Tuesday, November 8, 2011

Regeneron Trade Closed; FDA Ruling Imminent:


Write-up explained what we thought was the best risk-reward  strategy for trading REGN options ahead of the FDA's ruling on Eylea; a drug for Wet Age-Related Macular Degeneration (AMD).

FDA decision on Eylea is Imminent.

If you're not a subscriber but would like to receive future trades, please use Paypal in the right margin for a Quarter or Year through February 2013.

Cheers from the Psychology of the Call team (POTC) and the Ambassador of Truth through the 2012 U.S. Presidential Election:

Capitalist Pig Bob : /

8 comments:

Anonymous said...

thank u guys, interesting trade, end result will matter tho- Ashok

Anonymous said...

We want the decision to come before 18, we went with the nov's..xcellent stuff, Sara.

Anonymous said...

with that ashok, what will count is the final cash amt in my acct! J. Singh.

POTC said...

We agree Singh, the only thing that matters is your profit line aft FDA rules. Be sure we are confident in our analysis though. Best, Adam.

POTC said...

Dear Sara, we can't give too much info here obviously, we'll email you abt the month.
potc-

Anonymous said...

Just opened my mailbox and it was very very well written guys. GO fda.

Anonymous said...

the value of Eylea is going to rest on the pricing, everybody expects this to pass buddy, fyi

Anonymous said...

worrying we are not getting volume guys, pricing does not worry me- Ashok